Real-World Use of Biologics in the Treatment of Psoriasis and Ankylosing Spondylitis in China: The Case of Secukinumab
Author(s)
Mengying Wang, Master of Midicine, xiaoyang xu, MSC, Xiaoning He, PhD, Jing Wu, PhD.
Tianjin University, Tianjin, China.
Tianjin University, Tianjin, China.
Presentation Documents
OBJECTIVES: To evaluate the patient characteristics, treatment pattern, and economic burden of patients with psoriasis and ankylosing spondylitis in China treated with biologics of Secukinumab.
METHODS: This study utilized data from the electronic medical records (EMR) of more than 80 secondary and tertiary hospitals in Tianjin, China. Patients who initiated the use of Secukinumab under the diagnosis of psoriasis or ankylosing spondylitis between 2017 and 2023 were identified. The index date was defined as the date of the first prescription of Secukinumab. The patient characteristics, annual number of Secukinumab prescriptions, all-cause and disease-specific healthcare resource utilization and costs during the first year of follow-up were described.
RESULTS: A total of 1,306 psoriasis patients were included, with a mean age of 44.1±14.0 years, and 66.8% were male. The annual average number of Secukinumab prescriptions per patient was 12.9±9.2 (median: 12, [IQR:4,20]). The disease-specific costs during the 1st follow-up year amounted to ¥19,771±13,175, with 84.9% attributed to drug costs. For ankylosing spondylitis, 215 patients were included, with a mean age of 36±9.7 years, and 85.6% were male. The annual average number of Secukinumab prescriptions per patient was considerably lower than that for psoriasis patients, at 6.6±3.7 (median:6, [IQR:4,9]). The disease-specific costs in the first year accounted for 76% (¥10,799 ± 6,516) of the total direct medical costs (¥14,226 ± 9,467), which was lower than in the psoriasis cohort.
CONCLUSIONS: The majority of patients with psoriasis and ankylosing spondylitis did not achieve the recommended number of prescriptions as outlined in the drug's labeling. Patients with ankylosing spondylitis had a lower number of prescriptions compared to those with psoriasis. Overall, patients with both psoriasis and ankylosing spondylitis faced a significant economic burden, necessitating optimization of treatment plans and rational allocation of medical resources to alleviate the financial burden on patients.
METHODS: This study utilized data from the electronic medical records (EMR) of more than 80 secondary and tertiary hospitals in Tianjin, China. Patients who initiated the use of Secukinumab under the diagnosis of psoriasis or ankylosing spondylitis between 2017 and 2023 were identified. The index date was defined as the date of the first prescription of Secukinumab. The patient characteristics, annual number of Secukinumab prescriptions, all-cause and disease-specific healthcare resource utilization and costs during the first year of follow-up were described.
RESULTS: A total of 1,306 psoriasis patients were included, with a mean age of 44.1±14.0 years, and 66.8% were male. The annual average number of Secukinumab prescriptions per patient was 12.9±9.2 (median: 12, [IQR:4,20]). The disease-specific costs during the 1st follow-up year amounted to ¥19,771±13,175, with 84.9% attributed to drug costs. For ankylosing spondylitis, 215 patients were included, with a mean age of 36±9.7 years, and 85.6% were male. The annual average number of Secukinumab prescriptions per patient was considerably lower than that for psoriasis patients, at 6.6±3.7 (median:6, [IQR:4,9]). The disease-specific costs in the first year accounted for 76% (¥10,799 ± 6,516) of the total direct medical costs (¥14,226 ± 9,467), which was lower than in the psoriasis cohort.
CONCLUSIONS: The majority of patients with psoriasis and ankylosing spondylitis did not achieve the recommended number of prescriptions as outlined in the drug's labeling. Patients with ankylosing spondylitis had a lower number of prescriptions compared to those with psoriasis. Overall, patients with both psoriasis and ankylosing spondylitis faced a significant economic burden, necessitating optimization of treatment plans and rational allocation of medical resources to alleviate the financial burden on patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD13
Topic
Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks, Health & Insurance Records Systems
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), STA: Biologics & Biosimilars